Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer

Tianhong Li, Bilal Piperdi, William V. Walsh, Mimi Kim, Laurel A. Beckett, Rasim A. Gucalp, Missak Haigentz, Venu G. Bathini, Huiyu Wen, Kaili Zhou, Patricia B. Pasquinelli, Srikanth Gajavelli, Meera Sreedhara, Xianhong Xie, Primo N. Lara, David R. Gandara, Roman Perez-Soler

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Micro-Abstract This randomized phase 2 study demonstrated promising clinical synergism between pemetrexed and intercalated erlotinib in patients with unselected nonsquamous non–small-cell lung cancer (NSCLC) as second-line therapy. EGFR (epidermal growth factor receptor) genotyping by Sequenom multiplex oncogenotyping assay was feasible in 79% of eligible patients using tumor DNA from either archival specimens and/or plasma. Because patients with EGFR-mutant NSCLC respond well to EGFR tyrosine kinase inhibitor monotherapy alone or in combination with bevacizumab, the combination might merit further evaluation as second-line or maintenance therapy against new standards in patients with EGFR wild-type advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)60-67
Number of pages8
JournalClinical Lung Cancer
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Pemetrexed
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Erlotinib Hydrochloride
DNA
Therapeutics
Neoplasms

Keywords

  • EGFR wild type
  • Multiplex genotyping
  • Plasma circulating tumor DNA
  • Randomized phase 2 study
  • Second line

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer. / Li, Tianhong; Piperdi, Bilal; Walsh, William V.; Kim, Mimi; Beckett, Laurel A.; Gucalp, Rasim A.; Haigentz, Missak; Bathini, Venu G.; Wen, Huiyu; Zhou, Kaili; Pasquinelli, Patricia B.; Gajavelli, Srikanth; Sreedhara, Meera; Xie, Xianhong; Lara, Primo N.; Gandara, David R.; Perez-Soler, Roman.

In: Clinical Lung Cancer, Vol. 18, No. 1, 01.01.2017, p. 60-67.

Research output: Contribution to journalArticle

Li, Tianhong ; Piperdi, Bilal ; Walsh, William V. ; Kim, Mimi ; Beckett, Laurel A. ; Gucalp, Rasim A. ; Haigentz, Missak ; Bathini, Venu G. ; Wen, Huiyu ; Zhou, Kaili ; Pasquinelli, Patricia B. ; Gajavelli, Srikanth ; Sreedhara, Meera ; Xie, Xianhong ; Lara, Primo N. ; Gandara, David R. ; Perez-Soler, Roman. / Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer. In: Clinical Lung Cancer. 2017 ; Vol. 18, No. 1. pp. 60-67.
@article{8ce8410d476a49f0991775eee7dc1e15,
title = "Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer",
abstract = "Micro-Abstract This randomized phase 2 study demonstrated promising clinical synergism between pemetrexed and intercalated erlotinib in patients with unselected nonsquamous non–small-cell lung cancer (NSCLC) as second-line therapy. EGFR (epidermal growth factor receptor) genotyping by Sequenom multiplex oncogenotyping assay was feasible in 79{\%} of eligible patients using tumor DNA from either archival specimens and/or plasma. Because patients with EGFR-mutant NSCLC respond well to EGFR tyrosine kinase inhibitor monotherapy alone or in combination with bevacizumab, the combination might merit further evaluation as second-line or maintenance therapy against new standards in patients with EGFR wild-type advanced NSCLC.",
keywords = "EGFR wild type, Multiplex genotyping, Plasma circulating tumor DNA, Randomized phase 2 study, Second line",
author = "Tianhong Li and Bilal Piperdi and Walsh, {William V.} and Mimi Kim and Beckett, {Laurel A.} and Gucalp, {Rasim A.} and Missak Haigentz and Bathini, {Venu G.} and Huiyu Wen and Kaili Zhou and Pasquinelli, {Patricia B.} and Srikanth Gajavelli and Meera Sreedhara and Xianhong Xie and Lara, {Primo N.} and Gandara, {David R.} and Roman Perez-Soler",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.cllc.2016.10.003",
language = "English (US)",
volume = "18",
pages = "60--67",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer

AU - Li, Tianhong

AU - Piperdi, Bilal

AU - Walsh, William V.

AU - Kim, Mimi

AU - Beckett, Laurel A.

AU - Gucalp, Rasim A.

AU - Haigentz, Missak

AU - Bathini, Venu G.

AU - Wen, Huiyu

AU - Zhou, Kaili

AU - Pasquinelli, Patricia B.

AU - Gajavelli, Srikanth

AU - Sreedhara, Meera

AU - Xie, Xianhong

AU - Lara, Primo N.

AU - Gandara, David R.

AU - Perez-Soler, Roman

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Micro-Abstract This randomized phase 2 study demonstrated promising clinical synergism between pemetrexed and intercalated erlotinib in patients with unselected nonsquamous non–small-cell lung cancer (NSCLC) as second-line therapy. EGFR (epidermal growth factor receptor) genotyping by Sequenom multiplex oncogenotyping assay was feasible in 79% of eligible patients using tumor DNA from either archival specimens and/or plasma. Because patients with EGFR-mutant NSCLC respond well to EGFR tyrosine kinase inhibitor monotherapy alone or in combination with bevacizumab, the combination might merit further evaluation as second-line or maintenance therapy against new standards in patients with EGFR wild-type advanced NSCLC.

AB - Micro-Abstract This randomized phase 2 study demonstrated promising clinical synergism between pemetrexed and intercalated erlotinib in patients with unselected nonsquamous non–small-cell lung cancer (NSCLC) as second-line therapy. EGFR (epidermal growth factor receptor) genotyping by Sequenom multiplex oncogenotyping assay was feasible in 79% of eligible patients using tumor DNA from either archival specimens and/or plasma. Because patients with EGFR-mutant NSCLC respond well to EGFR tyrosine kinase inhibitor monotherapy alone or in combination with bevacizumab, the combination might merit further evaluation as second-line or maintenance therapy against new standards in patients with EGFR wild-type advanced NSCLC.

KW - EGFR wild type

KW - Multiplex genotyping

KW - Plasma circulating tumor DNA

KW - Randomized phase 2 study

KW - Second line

UR - http://www.scopus.com/inward/record.url?scp=85007426193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007426193&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2016.10.003

DO - 10.1016/j.cllc.2016.10.003

M3 - Article

C2 - 27919627

AN - SCOPUS:85007426193

VL - 18

SP - 60

EP - 67

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 1

ER -